DIA-39-C20
WEIGHT MANAGEMENTQuick Specifications
| Vial Size | 10MG |
|---|---|
| BAC Water | 1ML |
| Amount Per Unit | 0.1MG PER UNIT |
| Recommended Dose | TITRATE UP FROM 2.5MG TO 10MG (25 TO 100 UNITS) |
| Frequency | 1X PER WEEK |
| Injection Type | SUBCUTANEOUS |
| Timing | Same Day Every Week / Starting Dose Is 2.5 MG — Titrate Slowly |
Research Overview
DIA-39-C20 (Dual Regulator) is a 39-amino acid dual incretin agonist belonging to the Peptide Receptor Modulator Research Series. It simultaneously targets both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR), producing synergistic — not merely additive — metabolic effects through co-activation of overlapping downstream signaling pathways. The backbone is engineered from a GIP-based scaffold with Aib substitutions at positions 2 and 13 for DPP-4 resistance, and carries a C20 fatty diacid (eicosanedioyl) side chain via a γ-Glu-2x AEEA linker for albumin binding and extended once-weekly half-life. CAS: 2023788-19-2. Structurally analogous in class to tirzepatide. Once-weekly subcutaneous injection. Key reference literature: Coskun et al. (Cell Metabolism 2022) — LY3437943 triple receptor agonist, discovery to clinical proof; Urva et al. (Lancet 2022) — Phase 1b multiple-ascending dose trial; Jastreboff et al. (NEJM 2022) — tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).
Commonly Studied With
These peptides are frequently researched alongside Dual Regulator (DIA-39-C20): 10mg due to complementary mechanisms:
Dual Regulator (DIA-39-C20): 10mg information on this page is for research and educational purposes only. This content is not FDA-approved, does not constitute medical advice, and should not be used to guide personal health decisions. Consult a qualified healthcare professional before using any research compound.
Dose Calculator
Enter your target dose to calculate the volume to draw.
Recommended dose: TITRATE UP FROM 2.5MG TO 10MG (25 TO 100 UNITS)